Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of amivantamab and lazertinib with platinum-pemetrexed chemotherapy after osimertinib failure in EGFR-mutated NSCLC
MOH_2021-10-13_010308Phase 3Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab, lazertinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Johnson & Johnson. Primary endpoint: Progression-free survival. Started Aug 2021; status: active, not recruiting.
02
Drugs
amivantamablazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2021-10-13_010308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-13_010308.